About the Company
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SGEN News
Pfizer lifts profit view on cost cuts, demand for COVID products
Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, ...
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid decline
Pfizer Inc. (NYSE: PFE) has announced its financial outcomes for the first quarter of 2024, displaying strong performance in ...
Pfizer Beats Estimates for the First Quarter
The pharma giant's earnings surpassed Wall Street's expectations despite revenue declines from its COVID-19 products.
Another Seagen win, with full FDA approval for Pfizer’s Tivdak
Developed by Seagen, now a part of US pharma giant Pfizer (NYSE: PFE), and Denmark’s Genmab (OMX: GEN), Tivdak received accelerated approval for this indication in 2021. The drug is now co-owned by ...
Seagen Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pfizer Profits Drop On Lower Covid-19 Product Sales
Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other ...
Two Brothers, a Big Biotech Bet and an $8 Billion Payout
A two-decade bet on a biotechnology company turned into a roughly $8 billion windfall for investors in a New York hedge fund earlier this year.
ANALYSIS-China's biotech sector comes of age with big licensing deals, global ambitions
then a major licensing deal RemeGen Co Ltd struck last month with Seattle-based Seagen Inc fits the bill. The agreement to co-develop cancer treatments using a RemeGen antibody drug conjugate is ...
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock ...
Seagen Inc. (SGEN.MX)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Penske Automotive Group, Inc. (NYSE:PAG) Q1 2024 Earnings Call Transcript
Q1 2024 Earnings Call April 30, 2024 Penske Automotive Group, Inc. isn’t one of the 30 most popular stocks among hedge funds ...
Pfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue Decline
The company's financial health remains robust, underscored by a decrease in cost of sales and operational efficiencies.
Loading the latest forecasts...